Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

YS

YS Biopharma Co Ltd

May 17 • 04:00PM ET

0.9779

Dollar change +0.0278
Percentage change 2.93	%

Healthcare • Biotechnology • China • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	90.47%	Shs Outstand	188.33M	Perf Week	0.81%
Market Cap	184.17M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	17.94M	Perf Month	14.37%
Income	-	PEG	-	EPS next Q	-0.08	Inst Own	2.71%	Short Float	0.32%	Perf Quarter	142.05%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	0.15%	Short Ratio	0.31	Perf Half Y	48.39%
Book/sh	0.72	P/B	1.36	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf Year	-19.84%
Cash/sh	0.17	P/C	5.86	EPS next 5Y	-	ROE	-	52W Range	0.35 - 1.78	Perf YTD	91.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.06%	Beta	0.69
Dividend TTM	-	Quick Ratio	0.72	Sales past 5Y	-	Gross Margin	-	52W Low	179.16%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.94	EPS Y/Y TTM	624.41%	Oper. Margin	0.00%	RSI (14)	60.46	Volatility	12.44% 11.49%
Employees	-	Debt/Eq	1.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.17
Option/Short	No / Yes	LT Debt/Eq	0.27	EPS Q/Q	-215.70%	Payout	-	Rel Volume	0.34	Prev Close	0.95
Sales Surprise	15.54%	EPS Surprise	-45.56%	Sales Q/Q	-	Earnings	Apr 19 BMO	Avg Volume	185.58K	Price	0.98
SMA20	17.15%	SMA50	24.25%	SMA200	40.02%	Trades		Volume	62,327	Change	2.93%

May-07-24 04:20PM	YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer (PR Newswire)
Apr-29-24 08:00AM	YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire)
Apr-22-24 09:10AM	YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript (Insider Monkey)
Apr-19-24 11:52AM	YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024 (InvestorPlace) -15.16%
07:00AM	YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 (PR Newswire)
08:00AM	Loading…
Apr-18-24 08:00AM	YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine (PR Newswire) -8.65%
Apr-16-24 08:00AM	YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 (PR Newswire)
Apr-09-24 10:06AM	YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout (FierceBiotech.com)
08:00AM	YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine (PR Newswire)
Apr-03-24 08:00AM	YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility (PR Newswire) +12.42%
Mar-05-24 08:00AM	YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries (PR Newswire) +32.03%
Feb-22-24 05:00PM	YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 (PR Newswire)
Feb-18-24 04:30AM	/C O R R E C T I O N -- YS Biopharma Co., Ltd./ (PR Newswire)
Feb-16-24 08:20PM	YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting (PR Newswire)
05:36PM	Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd. (PR Newswire)
08:00AM	Loading…
Feb-14-24 08:00AM	YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance (PR Newswire)
07:50AM	YS Biopharma Announces Appointment of New Directors (PR Newswire)
Feb-12-24 08:50AM	YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. (PR Newswire)
Feb-09-24 06:30AM	YS Biopharma Announces US$40 Million Private Placement Financing (PR Newswire)
Feb-08-24 06:10PM	Shareholders of YS Biopharma Announce an Extraordinary General Meeting (PR Newswire)
Jan-24-24 04:00PM	Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire)
Jan-22-24 10:51PM	YS Stock Earnings: YS Biopharma Co Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:00PM	YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 (PR Newswire)
Jan-08-24 08:00AM	YS Biopharma Announces Changes to its Board Committees (PR Newswire) +7.00%
Dec-20-23 04:30PM	YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting (PR Newswire) -11.76%
04:15PM	/DISREGARD RELEASE: YS Biopharma/ (PR Newswire)
08:56AM	YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023 (PR Newswire)
Nov-14-23 08:30AM	Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target (PR Newswire)
Oct-31-23 08:30AM	YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine (PR Newswire)
Oct-26-23 08:30AM	YS Biopharma Announces Receipt of Nasdaq Notice (PR Newswire) -15.06%
08:00AM	Loading…
Oct-10-23 08:00AM	UPDATE - Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire)
Sep-26-23 08:30AM	YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine (PR Newswire)
Sep-20-23 08:00AM	Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire)
Sep-15-23 08:30AM	YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection (PR Newswire)
Sep-05-23 08:30AM	YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference (PR Newswire)
Aug-24-23 04:15PM	YS Biopharma Announces Purchase of Shares by Company Officers (PR Newswire)
Aug-17-23 08:00AM	Diamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire) -6.36%
Aug-15-23 05:00PM	YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 (PR Newswire)
Aug-10-23 04:30PM	YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 (PR Newswire)
Jul-26-23 05:00PM	YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 (PR Newswire)
Jul-21-23 04:30PM	YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 (PR Newswire)
Jun-09-23 08:00AM	Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023 (GlobeNewswire)
Jun-08-23 01:45PM	YS Biopharma (NASDAQ:YS) shareholders have endured a 80% loss from investing in the stock a year ago (Simply Wall St.)
Jun-01-23 08:30AM	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA (PR Newswire) +10.60%
May-18-23 08:25AM	YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 (PR Newswire)
May-16-23 07:00AM	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan (PR Newswire)
Apr-18-23 07:00AM	YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023 (PR Newswire)
Mar-27-23 06:00AM	YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study (PR Newswire) -36.95%

YS Biopharma Co. Ltd. engages in discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

YS

YS Biopharma Co Ltd

Upgrade your FINVIZ experience